OtherConferences/Lectures His research has been presented nationally and internationally at numerous scientific meetings including: • The San Antonio Breast Cancer Symposium (SABCS) • American Association for Cancer Research (AACR) • Radiological Society of North America (RSNA) • National Cancer Research Institue (NCRI) • European Breast Cancer Conference (EBCC) • IMPAKT Breast Cancer Conference • Pathological Society of Great Britain & Ireland
Colin Purdie studied Medicine at the University of Edinburgh between 1980 and 1986. He studied for an intercalated degree and graduated with a first class honours in Pharmacology (BSc) and a primary medical degree (MBChB). Following his re-registration posts in clinical medicine and surgery he worked for 2 years in internal medicine before being awarded the prestigious Leckie-Mactier Fellowship by the University of Edinburgh. He embarked on a highly successful 3 year PhD which was awarded in 1994 and resulted in several publications including one in the journal Nature (Clarke, A.R et al. (1993) Nature 362: 849-851).
He went on to train in cellular pathology in Glasgow and Edinburgh between 1992 and 1997 including periods as a Clinical Lecturer in both the Universities of Edinburgh and Glasgow. He obtained the MRCPath by examination and was appointed as a Consultant Histopathologist in NHS Tayside in 1997. He was also appointed as an Honorary Senior Lecturer in the University of Dundee in 1997 and promoted to Honorary Reader in 2011. Since 2000 he has been a full-time specialist breast pathologist and Lead Clinician for Breast Pathology in Tayside.
His research interests are the molecular genetics of breast cancer and the relationship between the pathological features in the breast seen at a cellular level and those derived from radiological imaging (ultrasound, shear wave elastography, X-ray and magnetic resonance imaging). He is involved in collaborative research with numerous national and international groups in these fields.
WORK FOR INTERNATIONAL BODIES
International Cancer Genome Consortium (ICGC)
Member of Breast Pathology Working Group, 2011 – Current.
European Organisation for Research and Treatment of Cancer (EORTC)
Member of research project review group, 2016 - Current.
Breast Cancer Now Tissue Bank
Member of Tissue Access Committee, 2011 – 2015.
Egyptian Society of Pathology
Invited Lecturer, 2014.
Breast Cancer Research
Editorial Board member, 2015 - Current.
WORK FOR NATIONAL BODIES
UK Breast Screening Programme
Member of Pathology committee, 2017 - Current.
Scottish Breast Screening Programme
Chair of Pathology QA committee, 2017 - Current.
Member of Pathology QA committee, 2006 - 2017.
Royal College of Pathologists
Member of Specialty Advisory Committee on Histopathology, 2005 – 2009.
Association of Clinical Pathologists
Secretary & Treasurer Caledonian Branch, 1999 – 2004.
Member of Histopathology Committee, 2001 – 2005.
Chair of Histopathology Committee, 2005 – 2009.
Member of ACP National Council, 2005 – 2009.
National Institute for Health and Clinical Excellence
Consultant to NICE on proposed single technology proposal, 2010 – Current.
(Royal College of Pathologists, Breast Cancer Now)
National Cancer Research Institute
Member of NCRI Breast Clinical Studies Group, 2009 – Current.
British Breast Group
Elected member, 2009 – Current.
Scottish Cancer Trials Breast Group
Invited member, 2009 – Current.
Peer reviewer for scientific journals
Histopathology, Cancer, The Breast, Journal of Pathology, Journal of Clinical Pathology, British Journal of Cancer, European Journal of Cancer, Oncogene, British Journal of Surgery, Breast Cancer Research & Treatment, Pathology - Research and Practice and Breast Cancer Research.
Peer reviewer for Grant Awarding Bodies
Breast Cancer Now, 2015 - Current.
NHS Breast Screening Programme
Member NHS BSP Education Committee, 2004 – Current.
Pathology Update Course (annual) – Invited lecturer, 2005 – 2019.
National Cancer Quality Steering Group
Member Breast Cancer QPI Development Group, 2010 - Current.
Breast Cancer Now Tissue Bank
Grant holder, 2009 – 2015.
Member of Operations Group, 2009 – 2011.
Member of Tissue Access Committee, 2011 – 2015.
OPTIMA clinical trial (National Institute for Health Research)
Member of Trial Steering Committee, 2012 – Current.
ROSCO clinical trial (National Cancer Research Network)
Member of Trial Steering Committee, 2014 - Current.
Colin Purdie is a full-time consultant pathologist with NHS Tayside. All research is carried out in addition to his clinical commitments.
- In 2011 he was invited to join the International Cancer Genome Consortium (ICGC) as a member of Breast Pathology Working Group. This group is composed of the world’s top Breast Pathologists from Europe, North America and Australasia. Only 1 other Pathologist is from the UK.
The ICGC has carried out whole genome sequencing on a large number of breast cancers and the data analysis and publication is ongoing (his contributions are published in: Annals of Oncology https://doi.org/10.1093/annonc/mdy404 (2018), Nature 543: 714-718 (2017), Nature Genetics 49 (3), 341-348 (2017), Nature Communications 7: 12910 (2016), Nature 534: 47-54 (2106), Genome Res 25: 814-824 (2015)).
- His research career started in 1988 when he was awarded the Leckie-Mactier Fellowship at the University of Edinburgh.
- His PhD was entitled “The Role of p53 in colorectal carcinogenesis”.
- His supervisor was Prof Andrew H Wyllie, FRS.
- His examiners were Prof, Sir David Lane , FRS and Prof, Sir David Carter, FRSE.
- As part of his PhD he created a p53 gene knock-out mouse which provided the first demonstration of the link between p53 and apoptosis (programmed cell death). This seminal work was published and has been cited more than 2600 times in the world scientific literature (Nature 362: 849-52(1993)).
- His published scientific works have been cited more than 7,900 times with 3,500 of those in the last 5 years.
- He has been awarded grants totalling more than £9 million.
Głodzik D, Purdie C, Rye IH, Simpson P, Staaf J, Span PN, Russnes H, Nik-Zainal S. Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers. (2018) Annals of Oncology https://doi.org/10.1093/annonc/mdy404.
Cha J-H, Yang W-H, Xia W, Wei Y, Chan L-C, Lim S-O, Li C-W, Kim T, Chang S-S, Lee H-H, Hsu JL, Wang H-L, Kuo C-W, Chang W-C, Hadad S, Purdie CA, McCoy AM, Cai S, Tu Y, Litton JK, Mittendorf EA, Moulder SL, Symmans WF, Thompson AM, Piwnica-WormsH, Chen C-H, Khoo K-H, Hung M-C. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. (2018) Molecular Cell 71 (4): 606-620.
Yeap PM, Evans A, Purdie CA, Jordan LB, Vinnicombe SJ. A comparison of the imaging features of pleomorphic and classical invasive lobular carcinoma. (2018) Breast Cancer Res Treat https://doi.org/10.1007/s10549-018-4914-8.
Evans A, Whelehan P, Thompson A, Purdie C, Jordan L, Macaskill J, Waugh S, Fuller-Pace F, Brauer K, Vinnicombe S. Prediction of pathological complete response to neoadjuvant chemotherapy for primary breast cancer comparing interim ultrasound, shear wave elastography and MRI. (2018) Eur J Ultrasound 39 (4): 422-431.
Ahmeidat H, Purdie C, Jordan L, Fleming D, McCullough J, Evans A. Non-histopathological Parameters Associated with Upgrade of Breast Tumours Yielding a Core Biopsy report of Histological Grade 2 Ductal no Special Type to Grade 3 on Excision. (2018) Eur J Surg Onc https://doi.org/10.1016/j.ejso.2018.07.002.
Evans A, Whelehan P, Thompson A, Purdie C, Jordan L, Macaskill J, Henderson S, Vinnicombe S. Identification of pathological complete response after neoadjuvant chemotherapy for breast cancer: comparison of greyscale ultrasound, shear wave elastography, and MRI. (2018) Clin Radiol https://doi.org/10.1016/j.crad.2018.05.030
Evans A, Sim YT, Pourreyron C, Thompson A, Jordan L, Fleming D, Purdie C, Macaskill J, Vinnicombe S, Pharoah P. Pre-operative stromal stiffness measured by shear wave elastography is independently associated with breast cancer-specific survival. (2018) Breast Cancer Res Treat https://doi.org/10.1007/s10549-018-4836-5.
Henderson SA, Gowdh NM, Purdie CA, Jordan LB, Evans A, Brunton T, Thompson AM, Vinnicombe S. Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy. (2018) Br J Radiol 20180123.
Ju YS, Martincorena I, M Gerstung, Petljak M, Alexandrov LB, RahbariR, Wedge DC, Davies HR, Ramakrishna M, Fullam A, Martin S, Alder C, Patel N, Gamble S, O’Meara S, Giri DD, Sauer T, Pinder SE, Purdie CA, Borg Å, Stunnenberg H, van de Vijver M, Tan BKT, Caldas C, Tutt A, Ueno NT, van’t Veer LJ, Martens JWM, Sotiriou C, Knappskog S, Span PN, Lakhani SR, Eyfjörd JE, Børresen-Dale A-L, Richardson A, Thompson AM, Viari A, Hurles ME, Nik-Zainal S, Campbell PJ and Stratton MR. Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. (2017) Nature 543: 714-718.
Glodzik D, Morganella S, Davies H, Simpson PT, Li Y, Zou X, Diez-Perez J, Staaf J, Alexandrov LBSmid M, Brinkman AB, Rye IH, Russnes H, Raine K, Purdie CA, Lakhani SR, Thompson AM, Birney E, Stunnenberg, HG, van de Vijver MJ, Martens JWM, Børresen-Dale A-L, Richardson AL, Kong G, Viari A, Easton D, Evan G, Campbell PJ, Stratton MR and Nik-Zainal S. A somatic mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. (2017) Nature Genetics 49 (3), 341-348.
Smid M, Rodríguez-González FG, Sieuwerts A, Prager-Van der Smissen W, van der Vlugt-Daane M, van Galen A, Debets R, Meijer-Van Gelder M, van Deurzen C, Foekens J, Martens J, Nik-Zainal S, Butler A, Martin S, Davies H, Stratton M, Staaf J, Ringnér M, Brinkman A, Berentsen K, Stunnenberg H, van de Vijver M, Broeks A, Richardson A, Fatima A, Purdie C, Thompson A, Caldas C, Span P, Simpson P, Lakhani S, Van Laere S, Desmedt C, Tommasi S, Eyfjord J, Vincent-Salomon A, Futreal P, knappskog S, King T, Thomas G, Viari A, Langerod A, Børresen-Dale A-L, Birney E, Salgado R, van den Eynden G, and MacGrogan G. Integration of the breast cancer genome and transcriptome associates specific mutational signatures with immune response. (2016) Nature Communications 7: 12910.
Davies H, Morganella S, Purdie C, Jang SJ, Borgen E, Russnes H, Glodzik D, Zou X, Viari A, Richardson A, Borresen-Dale A-L, Thompson A, Eyfjörd J, Kong G, Stratton M, and Nik-Zainal S. Whole-genome sequencing reveals breast cancers with mismatch repair deficiency. (2017) Cancer Res 77: 4755–62.
Moss RM, Amin AS, Crews C, Purdie CA, Jordan LB, Iacoviello F, Evans A, Speller RD, Vinnicombe SJ. Correlation of X-ray diffraction signatures of breast tissue and their histopathological classification. (2017) Scientific Reports 7: 12998.
Evans A, Whelehan P, Thompson A, Purdie C, Jordan L, Macaskill J, Waugh S, Fuller-Pace F, Brauer K, Vinnicombe S. Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy for Primary Breast Cancer Comparing Interim Ultrasound, Shear Wave Elastography and MRI. (2017) Eur J Ultrasound doi: 10.1055/s-0043-111589.
Henderson S, Purdie C, Michie C, Evans A, Lerski R, Johnston M, Vinnicombe S, Thompson AM. Interim heterogeneity changes measured using entropy texture features on T2-weighted MRI at 3.0 T are associated with pathological response to neoadjuvant chemotherapy in primary breast cancer. (2017) Eur Radiol 27: 4602-4611.
Hadad SM, Jordan LB, Roy PG, Purdie CA, Iwamoto T, Pusztai L, Moulder-Thompson SL and Thompson AM. A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer. (2016) BMC Cancer 16: 745.
Gadea G, Arsic N, Fernandes K, Diot A, Joruiz SM, Abdallah S, Meuray V, Vinot S, Anguille C, Remenyi J, Khoury MP, Quinlan PR, Purdie CA, Jordan LB, Fuller-Pace FV, de Toledo M, Cren M, Thompson Al, Bourdon JC, Roux P. TP53 drives invasion through expression of its Δ133p53β variant. (2016) eLife 5, e14734.
Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Seok Ju Y, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn S-M, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim H-Y, King TA, Krishnamurthy S, Lee HJ, Lee J-Y, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van’t Veer L, Tutt A, Knappskog S, Tee Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale A-L, Richardson AL, Kong G, Thomas G and Stratton MR. The somatic genetics of breast cancer revealed by 560 whole genome sequences. (2016) Nature 534: 47-54.
Evans A, Purdie CA, Jordan L, Macaskill EJ, Flynn J, Vinnicombe S.Stiffness at shear-wave elastography and patient presentation predicts upgrade at surgery following an ultrasound-guided core biopsy diagnosis of ductal carcinoma in situ. (2016) Clinical Radiology 71: 1156-1159.
Giannotti E, Vinnicombe S, Thomson K, McLean D, Purdie C, Jordan L, Evans A. Shear wave elastography and grey scale assessment of palpable probably benign masses: is biopsy always required? (2016) Br J Radiol 89: 20150865.
Evans A, Sim YT, Thomson K, Jordan L, Purdie C, Vinnicombe SJ. Shear wave elastography of breast cancer: Sensitivity according to histological type in a large cohort. (2016) The Breast 26: 115 – 118.
Waugh SA, Purdie CA, Jordan LB, Vinnicombe S, Lerski RA, Martin P, Thompson AM. Magnetic resonance imaging texture analysis classification of primary breast cancer. (2016) European Radiology 26: 322–330.
Ju YS, Tubio JMC, MifsudW, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MTM, van't Veer LJ, Tan BKT, Aparicio S, Span PN, Martens JWM, Knappskog S, Vincent-Salomon A, Børresen-Dale A-L, Eyfjörd JE, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PJ, Stratton MR, ICGC Prostate Cancer Working Group, ICGC Bone Cancer Working Group, ICGC Breast Cancer Working Group. Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. (2015) Genome Res 25: 814-824.
Quinlan PR, Groves M, Jordan LB, Stobart H, Purdie CA, Thompson AM. The informatics challenges facing biobanks: A perspective from a United Kingdom biobanking network. (2015) Biopreserv Biobank 13: 363-370.
Akbar S, Jordan LB, Purdie CA, Thompson AM, McKenna SJ. Comparing computer-generated and pathologist-generated tumour segmentations for immunohistochemical scoring of breast tissue microarrays. (2015) Br J Cancer 113: 1075-1080.
Pinder SE, Rakha EA, Purdie CA, Bartlett JMS, Francis A, Stein RS, Thompson AM, Shaaban AM. Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches. (2015) Histopathology 67: 279-293.
Lin M-L, Patel H, Remenyi J, Banerji CRS, Lai C-F, Periyasamy M, Lombardo Y, Busonero C, Ottaviani S, Passey A, Quinlan PR, Purdie CA, Jordan LB, Thompson AM, Finn RS, Rueda OM, Caldas C, Gil J, Coombes CR, Fuller-Pace FV, Teschendorff AE, Buluwela L, Ali S. Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer. (2015) Oncotarget 6: 21685.
Hadad SM, Coates P, Jordan LB, Dowling RJO, Chang MC, Done SJ, Purdie CA, Goodwin PJ, Stambolic V, Moulder-Thompson S, Thompson AM. Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial. (2015) Breast Cancer Res Treat 150:149–155
Cooke SL, Shlien A, Marshall J, Pipinikas CP, Martincorena I, Tubio JMC, Li Y, Menzies A, Mudie L, Ramakrishna M, Yates L, Davies H, Bolli N, Bignell GR, Tarpey PS, Behjati S, Nik-Zainal S, Papaemmanuil E, Teixeira VH, Raine K, O'Meara S, Dodoran MS, Teague JW, Butler AP, Iacobuzio-Donahue C, Santarius T, Grundy RG, Malkin D, Greaves M, Munshi N, Flanagan AM, Bowtell D, Martin S, Larsimont D, Reis-Filho JS, Boussioutas A, Taylor JA, Hayes ND, Janes SM, Futreal PA, Stratton MR, McDermott U, Campbell PJ, ICGC Breast Cancer Group (Provenzano E, van de Vijver M, Richardson AL, Purdie C, Pinder S, MacGrogan G, Vincent-Salomon A, Larsimont D, Grabau D, Sauer T, Garred Ø, Ehinger A, Van den Eynden GG, van Deurzen CHM, Salgado R, Brock JE, Lakhani SR, Giri DD, Arnould L, Jacquemier J, Treilleux I, Caldas C, Chin S-F, Fatima A, Thompson AM, Stenhouse A, Foekens J, Martens J, Sieuwerts A, Brinkman A, Stunnenberg H, Span PN, Sweep F, Desmedt C, Sotiriou C, Thomas G, Broeks A, Langerod A, S, Simpson PT, van’t Veer L, Eyfjörd JE, Hilmarsdottir H, Jonasson JG, Børresen-Dale A-L, Lee MTM, Wong BH, Tan BKT & Hooijer GKJ): Processed pseudogenes acquired somatically during cancer development. (2014) Nature communications, 5:3644.
Bouchalova P, Nenutil R, Muller P, Hrstka R, Appleyard M, Murray K, Jordan LB, Purdie CA, Quinlan P, Thompson AM, B Vojtesek, Coates PJ. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status. (2014) J Pathol: 233: 238-246.
Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA, Thompson AM. Progesterone receptor expression is an independent prognostic variable in early breast cancer – a population based study. (2014) Br J Cancer: 110: 565-572.
Vinnicombe S, Whelehan P, Thomson K, McLean D, Purdie CA, Jordan LB, Hubbard S, Evans AJ. What are the characteristics of breast cancers misclassified as benign by quantitative ultrasound shear wave elastography? (2014) European Radiol: 24: 921-926.
Evans A, Rauchhaus P, Whelehan P, Thomson K, Purdie CA, Jordan LB, Michie CO, Thompson A, Vinnicombe S. Does shear wave ultrasound independently predict axillary lymph node metastasis in women with invasive breast cancer? (2014) Breast Cancer Res Treat: 143: 153-157.
Evans A, Armstrong S, Whelehan P, Thomson K, Rauchhaus P, Purdie C, Jordan L, Jones L, Thompson A, Vinnicombe S. Can shear-wave elastography predict response to neoadjuvant chemotherapy in women with invasive breast cancer? (2013) Br J Cancer: 109: 2798-2802.
Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee M-TM, Ambrosone CB, Beckmann MW, Choi J-Y, Dieudonné A-S, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park B-W, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin J-G, Stingl JC, Wegman P, Wingren S, Wu AHB, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE. CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-analysis of Heterogeneous Study Populations. (2013) Clinical Pharmacology & Therapeutics: 95; 216-227.
Mullen R, Purdie CA, Jordan LB, McLean D, Whelehan P, Vinnicombe S, Brown DC, Evans A. Can additional histopathological examination of ultrasound-guided axillary lymph node core biopsies improve preoperative diagnosis of primary breast cancer nodal metastasis? (2013) Clin Radiol 68: 704-707.
Schaverien MV, Purdie CA, Munnoch DA. Clinical value of internal mammary lymph node metastases found incidentally during free flap recipient vessel exposure. (2013) Eur J Surg Oncol 39: 608-612.
Dayal JHS, Sales MJ, Corver WE, Purdie CA, Jordan LB, Quinlan PR, Baker L, Ter Haar NT, Pratt NR, Thompson AM. Multiparameter DNA content analysis identifies distinct groups in primary breast cancer. (2013) Br J Cancer; 108: 873-880.
Moussa O, Purdie C, Vinnicombe S, Thompson AM. Biomarker discordance: prospective and retrospective evidence that biopsy of recurrent disease is of clinical utility (2012) Cancer Biomarkers: 12; 231-239.
Mullen R, Reiss M, Fleming D, Evans A, Purdie CA. Giant oendulous fibroma of the breast associated with a locally advanced carcinoma of the breast. (2012) The Breast Journal; 18: 602-603.
Perrier S, Woolston AM, Purdie CA, Kazmi S, Preece PE, Davey KJ, Schor SL, Schor AM. Migration Stimulating Factor (MSF): A Novel Biomarker of Breast Cancer Progression. (2012) Translational Medic S1:003.
Macaskill EJ, Dewar S, Purdie CA, Brauer K, Baker L, Brown DC. Sentinel node biopsy has a greater node positivity rate than axillary node sample: Results from a retrospective analysis. (2012) EJSO 38: 662-669.
Evans A, Whelehan P, Thomson K, Brauer K, Jordan L, Purdie C, McLean D, Baker L, Vinniconmbe S, Thompson A. Differentiating benign from malignant solid breast masses: value of shear wave elastography according to lesion stiffness combined with greyscale ultrasound according to BI-RADS classification. (2012) Br J Cancer 107: 224-229.
Evans A, Whelehan P, Thomson K, McLean D, Brauer K, Purdie C, Baker L, Jordan L, Rauchhaus P, Thompson A. Invasive Breast Cancer: Relationship between Shear-wave Elastographic Findings and Histologic Prognostic Factors. (2012) Radiology 263: 673-677.
King SI, Purdie CA, Bray SE, Quinlan PR, Jordan LB, Thompson AM, Meek DW. Immunohistochemical detection of Polo-like Kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome. (2012) Breast Cancer Research 14:R40
Mullen R, Macaskill EJ, Khalil A , Elseedawy E, Brown DC, Lee AC, Purdie CA, Jordan LB, Thompson AM. Involved anterior margins after breast conserving surgery: Is re-excision required? (2012) EJSO 38 302 – 306.
Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB, Thompson AM. Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies. (2011) Cancer Treat Rev 38: 708-714.
Lo Nigro C, Vivenza D, Monteverde M, Lattanzio L, Gojis O, Garrone O, Comino A, Merlano M, Quinlan PR, Syed N, Purdie CA, Thompson A, Palmieri C, Crook T. High frequency of complex TP53 mutations in CNS metastases from breast cancer. (2011) Br J Cancer 106: 397 – 404.
Macaskill EJ, Purdie CA, Jordan LB, McLean D, Whelehan P, Brown DC, Evans A. Axillary lymph node core biopsy for breast cancer metastases – How many needle passes are enough? (2011) Clinical Radiology 67: 417-419.
Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S, Hardie DG, Pusztai L, Moulder-Thompson S, Dewar JA, Thompson AM. Evidence for biological effects if metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. (2011) Breast Cancer Research and Treatment 128: 783-794.
Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, Purdie CA, Jordan LB, Ferraldeschi R, Latif A, Hadfield KD, Clarke RB, Ashcroft L, Evans DG, Howell A, Nikoloff M, Lawrence J & Newman WG. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. (2011). Breast Cancer Research and Treatment. 125: 279- 87
Martin AJ, Grant A, Ashfield AM, Palmer CN, Baker L, Quinlan PR, Purdie CA, Thompson AM, Jordan LB & Berg JN. FGFR2 protein expression in breast cancer: nuclear localisation and correlation with patient genotype. (2011) BMC Research Notes. 4:72.
Bourdon J-C, Khoury MP, Diot A, Baker L, Fernandes K, Aoubala M, Quinlan P, Purdie CA, Jordan LB, Prats A-C, Lane DP, Thompson AM, p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. (2011) Breast Cancer Research. 13:R7
Evans A, Whelehan P, Thomson K, Mclean D, Brauer K, Purdie C, Jordan L, Baker L & Thompson A. Quantitative shear wave ultrasound elastography: initial experience in solid breast masses. (2010) Breast Cancer Research. 12:R104.
Thompson AM, Jordan LB, Quinlan P, Anderson, E, Skene A, Dewar JA & Purdie CA. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). (2010). Breast Cancer Research. 12: R92.
Purdie CA, McLean D, Stormonth E, Macaskill EJ, McCullough JB, Edwards SL, Brown DC & Jordan LB. Management of in situ lobular neoplasia detected on needle core biopsy of breast. (2010). J Clin Path. 63: 987–993.
Purdie CA, Baker L, Ashfield A,Chatterjee S, Jordan LB, Quinlan P, Adamson DJA, Dewar JA and Thompson AM. Increased mortality in HER2 positive, oestrogen positive invasive breast cancer: a population based study. (2010) Br J Cancer. 103: 475 – 481.
Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, Purdie CA, Jordan LB, Ferraldeschi R, Latif A, Hadfield KD, Clarke RB, Ashcroft L, Evans DG, Howell A, Nikoloff M, Lawrence J, Newman WG. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. (2010) Breast Cancer Research and Treatment. 125: 279-285.
Coates PJ, Appleyard MVCL, Murray K, Ackland C, Gardner J Brown DC, Adamson DJA, Jordan LB, Purdie CA, Munro AJ, Wright EG, Dewar JA, Thompson AM. Differential Contextural Responses of Normal Human Breast epithelium to Ionizing Radiation in an In Vivo Xenograft Model. (2010) Cancer Research. 70: 9808-9815.
Moore HC, Jordan LB,. Bray SE, Baker L, Quinlan PR, Purdie CA, Thompson AM, Bourdon J-C and Fuller-Pace FV. The RNA helicase p68 modulates expression and function of the Δ133 isoform(s) of p53, and is inversely associated with Δ133p53 expression in breast cancer. (2010) Oncogene. 29: 6475–6484.
Purdie CA, Jordan LB, McCullough JB, Edwards SL, Cunningham J, Walsh M, Grant A, Pratt N and ThompsonAM. HER2 assessment on core biopsies using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma. (2010) Histopathology. 56: 702-707.
Baker L, Quinlan PR, Patten N, Ashfield A, Birse-Stewart-Bell L.-J, McCowan C, Bourdon J.-C, Purdie CA, Jordan LB, Dewar JA, Wu L and Thompson AM. P53 mutation, deprivation and poor prognosis in primary breast cancer. (2010) Br J Cancer. 102:719-726.
Roy PG, Pratt N, Purdie CA, Baker L, Ashfield A, Quinlan P and Thompson A.M. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer. (2010) Int J Cancer. 127: 355-360.
Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, Kellock D, Jordan LB, Purdie CA, Hardie DG, Fleming S and Thompson AM. Histological evaluation of AMPK signalling in primary breast cancer. (2009) BMC Cancer. 9:307.
Shah R, SmithP, Purdie C, QuinlanP, BakerL, AmanP, ThompsonAM and CrookT. The Prolyl 3-Hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer. (2009) Br J Cancer. 100:1687-1696.
Ansari B, Ogston SA, Purdie CA, Adamson DJ, Brown DC, Thompson AM. Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast. (2008) Br J Surg. 95:547-54.
Paulin FE, O'Neill M, McGregor G, Cassidy A, Ashfield A, Ali CW, Munro A.J., Baker L., Purdie C.A., Lane D.P., Thompson A.M.. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. (2008) BMC Cancer. 8:281.
Song C, Purdie CA, Brown SI, Frank T, and Vaidya JS. Dynamic response to heat--a novel physical characteristic of breast cancer. (2008) Int J Surg. 6:357-8.
Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad, SM, Bieche, I, Chabaud, S, Bachelot, T, Thompson, AM and Cohen, PA. A candidate molecular signature associated with tamoxifen failure in primary breast cancer. (2008) Breast Cancer Res. 10:R88.
Christie LJ., McKay FJ., Purdie CA., Robertson KE., Topping DA. and Levison DA. A simple and rapid approach to the problem of tissue contamination and patient identity in histopathologic specimens. (2006) Human Pathology. 37:1536-42.
Ansari B., Purdie CA. and Brown DC. Adult Langerhans cell histiocytosis mimicking Paget's disease of the nipple. (2005) Breast Journal. 11:281-2.
McCallum M., Baker C., Gillespie K., Cohen B., Stewart H., Leonard R., Cameron D., Leake R., Paxton J., Robertson A., Purdie C., Gould A. and Steel M. A prognostic index for operable, node-negative breast cancer. (2004) Br J Cancer. 90:1933-41.
Besarani D., Purdie CA. and Townell NH. Recurrent urachal adenocarcinoma. (2003) J Clin Path 56:882-882.
Zhou, W., Goodman, S.N., Galizia, G., Lieto, E., Ferroraccio, F., Pignatelli, C., Purdie, C.A., Piris, J., Morris, R., Harrison, D.J., Baty, P.B., Culliford, A., Romans, K.E., Montgomery, E.A., Choti, M.A., Kinzler, K.W. and Vogelstein, B. (2002) Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet 359:219-225.
Ball, H.M-L., Hupp, T.R., Ziyae, D., Purdie, C.A., Kernohan, N.M., and Thompson, A.M. (2001) Differential p53 protein expression in breast cancer fine needle aspirates: the potential for in vivo monitoring. Br J Cancer 85: 1102-1105.
Purdie, C.A. and Piris, J. (2000) Histopathology, mucinous differentiation and DNA Ploidy in relation to Prognosis in Colorectal Carcinoma. Histopathology 36:121-126.
Docherty, J.G., McGregor, J.R., Purdie, C.A., Galloway, D.J. and O'Dwyer P.J. (1995) Efficacy of tumouricidal agents in-vitro and in-vivo. Br J Surgery 82: 1050-1052.
Purdie, C.A., Piris, J., Bird, C.C. and Wyllie, A.H. (1995) Chromosome 17q allele loss is associated with lymph node metastasis in locally aggressive colorectal cancer. J Pathol 175: 297-302.
Cripps, K.J., Purdie, C.A., Carder, P.J., White, S., Komine, K., Bird, C.C. and Wyllie, A.H. (1994) A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma. Oncogene 9: 2739-2743.
Purdie, C.A., Harrison, D.J., Peter, A., Dobbie, L., White, S., Howie, S.E.M., Salter, D.M., Bird, C.C., Wyllie, A.H., Hooper, M.L. and Clarke, A.R. (1994) Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9: 603-609.
Wyllie AH, Carder PJ, Clarke AR, Cripps KJ, Gledhill S, Greaves MF, Griffiths S, Harrison DJ, Hooper ML, Morris RG, Purdie CA, and Bird CC (1994) Apoptosis in Carcinogenesis: The Role of p53. Cold Spring Harb Symp Quant Biol 59: 403-409.
Carder, P., Wyllie, A.H., Purdie, C.A., Morris, R.G., White, S., Piris, J. and Bird, C.C. (1993) Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogene 8: 1397-1401.
Clarke, A.R., Purdie, C.A., Harrison, D.J., Morris, R.G., Bird, C.C., Hooper, M.L. and Wyllie, A.H. (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-851.
Purdie, C.A., O'Grady, J., Piris, J., Wyllie, A.H. and Bird, C.C. (1991) p53 Expression in Colorectal Tumors. Am. J. Path. 138: 807-813.
Thompson AM, Dunlop MG, Dempster M, Purdie CA, Allshire RC and Hastie ND. (1990) Human colorectal-cancer, but not breast-cancer, shows a high frequency of chromosomal telomere shortening. Br J Cancer 62: 545-546.
Ashton-Rickardt PG, Dunlop MG, Nakamura Y, Morris RG, Purdie CA, Steel CM, Evans HJ, Bird CC and Wyllie AH. (1989) High frequency of APC loss in sporadic colorectal carcinoma due to breaks clustered in 5q21-22. Oncogene 4: 1169-1174.
Purdie CA and McLean D. Benign microcalcification and its differential diagnosis in breast screening. (2017) Diagnostic Histopathology. 23: 159–171.
Francis A,Bartlett J, Rae D, Pinder SE, Stein RC, Stobart H, Purdie CA, Rakha E, Thompson AM, Shaaban AM. Viewpoint: Availability of oestrogen receptor and HER2 status for the breast multidisciplinary meeting discussion; time to get it right. (2016) EJSO: 42: 994 – 998.
Pinder SE, Rakha E, Purdie CA, Bartlett JMS, Francis A, Stein RC, Thompson AM, Shaaban AM. Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment; review of pathological issues and suggested approaches. (2015) Histopathology: 67: 279 – 293.
Shaaban AM, Purdie CA, Bartlett JMS, Stein RC, Lane S, Francis A, Thompson AM, Pinder SE. HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice. (2014) J Clin Pathol: 67: 161-167.
Pinder SE, Brown JP, Gillett Ch, Purdie CA, Speirs V, Thompson AM, Shaaban AM. The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example. (2013) J Clin Pathol; 66: 167-177.
Purdie CA and McLean D. Benign microcalcification and its differential diagnosis in breast screening. (2009) Diagnostic Histopathology. 15:382-394.
Purdie C.A. Sentinel lymph node biopsy: Review of the literature and guidelines for pathological handling and reporting. (2007) Current Diagnostic Pathology. 13:106-115.
Purdie CA. Chapter 15: A Practical Approach to the use of Immunohistochemistry in the Diagnosis and Management of Breast Disease In: Problematic issues in breast pathology. Ed. Shousha S. (2016) Springer International Publishing AG.
Dewar JA, Thompson AM and Purdie CA. Diseases of the Breast. In: Medicine & Surgery; An Integrated Textbook. Eds. Lim E, Loke YK, Thompson, AM. (2007) Churchill Livingstone Elsevier.
Wyllie AH, Carder PJ, Clarke AR, Cripps KJ, Gledhill S, Greaves MF, Griffiths S, Harrison DJ, Hooper ML, Morris RG, Purdie CA and Bird CC. Apoptosis in Carcinogenesis: The Role of p53. In: Cold Spring Harb Symp Quant Biol 1994 59: 403-409;
He was invited to lecture to the Egyptian Society of Pathology in Cairo in 2014 on various subjects of breast cancer diagnostic pathology.
He is an invited lecturer on numerous national breast pathology training courses. These courses are for Consultant Pathologists improving their clinical diagnostic skills in breast pathology. They are taught by an invited group of the UK’s top Breast Pathologists.
- NHS Breast Screening Programme Pathology update course.
- Nottingham Breast Pathology Masterclass.
- British Division of the International Academy of Pathology (BDIAP) breast pathology symposium.
- Hammersmith Breast Pathology Course.
For the last 20 years he has taught the Pathology of Breast Disease to University of Dundee medical undergraduates as part of the Reproductive Medicine block in 3rd year
- This involves a seminar and 3 lectures.
- One of the lectures is a mock multidisciplinary team (MDT) discussion of patient management in breast disease. This brings together all aspects of the teaching block encouraging the students to integrate all of their learning in that block. This has been devised by him and is a very popular part of the course.
Every year he teaches on the Pathology Student Selected Component (SSC) in his specialist area of Breast Pathology.